BlueRock Therapeutics
Latest round
- Series A
Last raised
- Dec 2016
Total raised
- $225M
Investors
- 2
About BlueRock Therapeutics
Founded in 2016 and based in Cambridge, US, BlueRock Therapeutics specializes in cellular medicine aimed at treating degenerative diseases. The company was acquired by Bayer AG in August 2019 for up to USD 600 mn, with an upfront payment of USD 240 mn and additional payments tied to development milestones. The company has conducted 2 deals to date, with the most recent deal completed on August 8, 2019.BlueRock Therapeutics LP is a clinical-stage biotechnology company focused on developing advanced cell therapies for treating degenerative diseases. Their primary investigational therapies include OpCT-001, targeting primary photoreceptor diseases, and bemdaneprocel for Parkinson's disease. These therapies leverage cellular medicine to replace damaged cells, enhancing patient outcomes.BlueRock Therapeutics generates revenue through collaborations with major pharmaceutical companies and research organizations, allowing for co-development of therapies and shared proceeds from successful commercialization. The acquisition, which is anticipated to close in Q3 2019, includes performance-based incentives that could amount to an additional USD 360 mn, contingent on clinical milestones, supporting BlueRock's strategy to introduce new products and enhance its operational capabilities.
Who invested in BlueRock Therapeutics
2 investors across 1 round
See all investors in BlueRock Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 9, 2016
Amount
$225M
Investors
Questions about BlueRock Therapeutics
Who invested in BlueRock Therapeutics?
BlueRock Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BlueRock Therapeutics raised?
BlueRock Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BlueRock Therapeutics last raise money?
BlueRock Therapeutics's most recent round on record is a Series A, in Dec 2016.
What does BlueRock Therapeutics do?
Founded in 2016 and based in Cambridge, US, BlueRock Therapeutics specializes in cellular medicine aimed at treating degenerative diseases.
Where is BlueRock Therapeutics headquartered?
BlueRock Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like BlueRock Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BlueRock Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BlueRock Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.